ABSTRACT
BACKGROUND: The emergence of nutritional genomics and the availability of nutrigenetic tests, which use genetic information to identify food products suited/not suited to the individual nutrigenetic profile, allow defining personalized dietary advice. AIM: To compare personalized dietary advice provided to 24 Italian children by a nutrigenetic test based on the recommendations from 2 different, widely employed nutrient profiling (NP) schemes, the USA Health Claims (USAHC) and the Guidelines for Responsible Food Marketing to Children, published by the US Center for Science in the Public Interest (CSPI); the genetic test-NP agreement regarding 50 commonly eaten foods has been calculated. METHODS: Twelve normal-weight and 12 overweight children were recruited in the Trieste district (North-East Italy), and nutrigenetic testing was offered using the G-Diet® Nutrigenomic Kit. Variants of 20 genes were tested and personalized dietary advice was formulated for each subject. The agreement between the NP schemes and among the nutrigenomic indications and both profiles was computed using Cohen's κ. RESULTS: Agreement between the USAHC and CSPI schemes was very poor overall (Cohen's κ=0.66). The agreement among the nutrigenomic indications and profiles ranged overall from 0.43 to 0.74 for each nutrigenomic profile with the USAHC, and from 0.29 to 0.80 with the CSPI. CONCLUSION: Disagreement on food classification among different NP schemes and inconsistencies deriving from nutrigenetic tests advocate more research into this area.
Subject(s)
Gene Expression Profiling , Nutrigenomics/methods , Child , Child, Preschool , Fathers , Female , Genetic Testing/methods , Humans , Life Style , Male , Metabolome , Mothers , Obesity/genetics , Overweight/genetics , Predictive Value of TestsABSTRACT
Based on the available data, we speculated that changes in brain iron metabolism induced by L-DOPA might be associated with the neurotoxicity of L-DOPA. To investigate this possibility, the effects of L-DOPA on the expression of iron influx proteins [transferrin receptor (TfR) and divalent metal transporter 1 (DMT1)], iron efflux protein (ferroportin 1), and iron uptake in C6 glioma cells were determined in this study using Northern blot and Western blot analysis and the calcein method. The findings showed that treatment of C6 cells with different concentrations of L-DOPA (0-100 microM) did not affect the expression of mRNA and protein of TfR and DMT1 with iron-responsive element (+IRE) and protein of ferroportin 1. However, a significant increase in the expression of DMT1(-IRE) mRNA and protein was found in cells treated, respectively, with 10 and 30 microM L-DOPA (mRNA) and 1, 5, 10 and 30 microM L-DOPA (protein). The increase in DMT(-IRE) protein induced by L-DOPA treatment was in parallel with the increase in DMT(-IRE) mRNA. The levels of DMT1(-IRE) mRNA and protein peaked in the cells treated with 10 microM L-DOPA and then decreased progressively with increasing concentrations of L-DOPA. Further study demonstrated that treatment of the cells with 10 microM L-DOPA induced a significant increase in ferrous uptake by C6 glioma cells. The findings suggested that the increased DMT1(-IRE) expression might be partly associated with the neurotoxicity of L-DOPA. Clinical relevance of the findings needs to be investigated further.
Subject(s)
Brain/drug effects , Iron/metabolism , Levodopa/toxicity , Animals , Brain/metabolism , Cation Transport Proteins/genetics , Cation Transport Proteins/metabolism , Chelating Agents/pharmacology , Ion Transport/drug effects , Phenanthrolines/pharmacology , RNA, Messenger/analysis , RNA, Messenger/metabolism , Rats , Receptors, Transferrin/genetics , Receptors, Transferrin/metabolism , Tumor Cells, Cultured , Up-RegulationABSTRACT
In 1999, drug manufacturers introduced a class of NSAIDs called COX-2 inhibitors or coxibs. The drugs were avidly promoted directly to the consumers and became bestsellers from the start. Arthritis sufferers were eager to take medications that eased joint pain with less risk of causing gastrointestinal pain, bleeding and other side-effects. In the year after their introduction, doctors wrote over 100 million prescriptions for celecoxib (Celebrex) and rofecoxib (Vioxx). Celebrex is the sixth best-selling drug, with sales of more than US$ 4 billion since its debut in 1999. Vioxx had sales of US$ 2.6 billion in 2001. However, the coxibs increase the risk of heart attacks and strokes, and their price, in the USA, is obscene. The manufacturers faced a possibly complicit, toothless and bloodless FDA, and used every maneuvering to fleece the patients. We must now reflect on attitudes that we thought only belong to the tobacco industry. Fortunately, safe and active alternatives exist.
